Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Eledon Pharmaceuticals, Inc. Common Stock

ELDN

Eledon Pharmaceuticals Inc is a clinical stage biotechnology company using immunology expertise in targeting the CD40 Ligand pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis. Its compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40L, a well-validated biological target that has broad therapeutic potential. It operates as one reportable segment, focused on the development of tegoprubart, to develop therapies to protect transplanted organs and prevent rejection, and to treat ALS.

Last trade $1.98
Day change +$0.005 (+0.25%)
Day range $1.86 – $2.05
Volume 837,492
Market cap $166M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$166.39M
Price / earnings
—
Price / book
5.4×
Price / sales
—
EV / sales
—
EV / EBITDA
-1.83×

Profitability

Earnings per share
-$1.00
Return on assets
-78.85%
Return on equity
-273.05%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
6.3×
Quick ratio
6.3×
Cash ratio
0.59×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$78.36M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for ELDN, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$0$0$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0$0
Selling, general and administrative$3.91M$4.64M$3.98M$3.99M$4.1M$4.46M$4.43M$6.77M
Research and development$17.76M$18.23M$17.2M$17.49M$14.97M$20.28M$13.53M$17.93M
Total operating expenses$21.67M$22.87M$21.18M$21.48M$19.07M$24.73M$17.96M$24.7M
Operating income-$21.67M-$22.87M-$21.18M-$21.48M-$19.07M-$24.73M-$17.96M-$24.7M
Interest expense$0$0$0$0$0$0$0$0
Income before taxes-$3.93M-$31.63M-$39.03M-$10.41M-$17.46M-$11.22M-$6.5M-$44.19M
Income taxes$0$0$0$35K$0$0$0$431K
Net income-$3.93M-$31.63M-$39.03M-$10.45M-$17.46M-$11.22M-$6.5M-$44.62M
Net income attributable to common shareholders-$3.79M-$30.24M-$36.94M-$13.13M-$16.13M-$10.36M-$6M-$41.74M
EBITDA-$21.67M-$22.87M-$21.18M-$21.48M-$19.07M-$24.73M-$17.96M-$24.7M
Basic earnings per share-$0.03-$0.27-$0.33-$0.14-$0.21-$0.13-$0.08-$0.60
Diluted earnings per share-$0.03-$0.27-$0.33-$0.14-$0.21-$0.13-$0.08-$0.63

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Eledon Presents Updated Long-Term Phase 2 BESTOW Extension Study Results at the International Congress of The Transplantation Society

Eledon Pharmaceuticals announced updated Phase 2 BESTOW extension study results showing tegoprubart-treated kidney transplant patients maintained significantly higher kidney function (71 vs. 58 mL/min/1.73 m² eGFR at 24 months) compared to tacrolimus, with zero rejections beyond six months versus seven in the tacrolimus arm. The FDA granted Fast Track designation to tegoprubart for kidney transplant rejection prevention, and the company plans to initiate the Phase 3 LEGACY trial in Q4 2026.

GlobeNewswire Inc.

Eledon Pharmaceuticals to Participate in Cantor Global Healthcare Conference 2025

Eledon Pharmaceuticals' CEO will participate in a fireside chat at the Cantor Global Healthcare Conference, discussing the company's investigational product tegoprubart, an anti-CD40L antibody targeting immune-modulating therapies for conditions like kidney transplantation and ALS.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Oct 5, 20201-for-18reverse split